These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 17595656)

  • 1. Clinical pharmacodynamic factors in docetaxel toxicity.
    Puisset F; Alexandre J; Treluyer JM; Raoul V; Roché H; Goldwasser F; Chatelut E
    Br J Cancer; 2007 Aug; 97(3):290-6. PubMed ID: 17595656
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence of amifostine on the toxicity and pharmacokinetics of docetaxel in metastatic breast cancer patients: a pilot study.
    Freyer G; Hennebert P; Awada A; Gil T; Kerger J; Selleslags J; Brassinne C; Piccart M; de Valeriola D
    Clin Cancer Res; 2002 Jan; 8(1):95-102. PubMed ID: 11801544
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Population pharmacokinetic-pharmacodynamic modeling and model-based prediction of docetaxel-induced neutropenia in Japanese patients with non-small cell lung cancer.
    Fukae M; Shiraishi Y; Hirota T; Sasaki Y; Yamahashi M; Takayama K; Nakanishi Y; Ieiri I
    Cancer Chemother Pharmacol; 2016 Nov; 78(5):1013-1023. PubMed ID: 27709284
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I trial of intraperitoneal docetaxel in the treatment of advanced malignancies primarily confined to the peritoneal cavity: dose-limiting toxicity and pharmacokinetics.
    Morgan RJ; Doroshow JH; Synold T; Lim D; Shibata S; Margolin K; Schwarz R; Leong L; Somlo G; Twardowski P; Yen Y; Chow W; Lin P; Paz B; Chu D; Frankel P; Stalter S
    Clin Cancer Res; 2003 Dec; 9(16 Pt 1):5896-901. PubMed ID: 14676112
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alpha-1-acid glycoprotein as an independent predictor for treatment effects and a prognostic factor of survival in patients with non-small cell lung cancer treated with docetaxel.
    Bruno R; Olivares R; Berille J; Chaikin P; Vivier N; Hammershaimb L; Rhodes GR; Rigas JR
    Clin Cancer Res; 2003 Mar; 9(3):1077-82. PubMed ID: 12631610
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic drug monitoring for the individualization of docetaxel dosing: a randomized pharmacokinetic study.
    Engels FK; Loos WJ; van der Bol JM; de Bruijn P; Mathijssen RH; Verweij J; Mathot RA
    Clin Cancer Res; 2011 Jan; 17(2):353-62. PubMed ID: 21224369
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effects of advanced age and serum α
    Kenmotsu H; Imamura CK; Ono A; Omori S; Nakashima K; Wakuda K; Taira T; Naito T; Murakami H; Takahashi T; Tanigawara Y
    Br J Clin Pharmacol; 2017 Nov; 83(11):2416-2425. PubMed ID: 28640540
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacogenetic screening of CYP3A and ABCB1 in relation to population pharmacokinetics of docetaxel.
    Bosch TM; Huitema AD; Doodeman VD; Jansen R; Witteveen E; Smit WM; Jansen RL; van Herpen CM; Soesan M; Beijnen JH; Schellens JH
    Clin Cancer Res; 2006 Oct; 12(19):5786-93. PubMed ID: 17020985
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relationship of systemic exposure to unbound docetaxel and neutropenia.
    Baker SD; Li J; ten Tije AJ; Figg WD; Graveland W; Verweij J; Sparreboom A
    Clin Pharmacol Ther; 2005 Jan; 77(1):43-53. PubMed ID: 15637530
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Population pharmacokinetic-pharmacodynamic model for neutropenia with patient subgroup identification: comparison across anticancer drugs.
    Kloft C; Wallin J; Henningsson A; Chatelut E; Karlsson MO
    Clin Cancer Res; 2006 Sep; 12(18):5481-90. PubMed ID: 17000683
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical trial simulation of docetaxel in patients with cancer as a tool for dosage optimization.
    Veyrat-Follet C; Bruno R; Olivares R; Rhodes GR; Chaikin P
    Clin Pharmacol Ther; 2000 Dec; 68(6):677-87. PubMed ID: 11180028
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prospective evaluation of the pharmacokinetics and toxicity profile of docetaxel in the elderly.
    ten Tije AJ; Verweij J; Carducci MA; Graveland W; Rogers T; Pronk T; Verbruggen MP; Dawkins F; Baker SD
    J Clin Oncol; 2005 Feb; 23(6):1070-7. PubMed ID: 15718305
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mechanism-based models for topotecan-induced neutropenia.
    Léger F; Loos WJ; Bugat R; Mathijssen RH; Goffinet M; Verweij J; Sparreboom A; Chatelut E
    Clin Pharmacol Ther; 2004 Dec; 76(6):567-78. PubMed ID: 15592328
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Population pharmacokinetic and pharmacodynamic analysis for time courses of docetaxel-induced neutropenia in Japanese cancer patients.
    Ozawa K; Minami H; Sato H
    Cancer Sci; 2007 Dec; 98(12):1985-92. PubMed ID: 17888031
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Factors affecting pharmacokinetic variability following doxorubicin and docetaxel-based therapy.
    Rudek MA; Sparreboom A; Garrett-Mayer ES; Armstrong DK; Wolff AC; Verweij J; Baker SD
    Eur J Cancer; 2004 May; 40(8):1170-8. PubMed ID: 15110880
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Bayesian population PK-PD model for ispinesib/docetaxel combination-induced myelosuppression.
    Kathman SJ; Williams DH; Hodge JP; Dar M
    Cancer Chemother Pharmacol; 2009 Feb; 63(3):469-76. PubMed ID: 18443793
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lack of effect of aprepitant on the pharmacokinetics of docetaxel in cancer patients.
    Nygren P; Hande K; Petty KJ; Fedgchin M; van Dyck K; Majumdar A; Panebianco D; de Smet M; Ahmed T; Murphy MG; Gottesdiener KM; Cocquyt V; van Belle S
    Cancer Chemother Pharmacol; 2005 Jun; 55(6):609-16. PubMed ID: 15723220
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Population analysis of the pharmacokinetics and the haematological toxicity of the fluorouracil-epirubicin-cyclophosphamide regimen in breast cancer patients.
    Sandström M; Lindman H; Nygren P; Johansson M; Bergh J; Karlsson MO
    Cancer Chemother Pharmacol; 2006 Aug; 58(2):143-56. PubMed ID: 16465545
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase I and pharmacokinetic study of exisulind and docetaxel in patients with advanced solid tumors.
    Witta SE; Gustafson DL; Pierson AS; Menter A; Holden SN; Basche M; Persky M; O'Bryant CL; Zeng C; Baron A; Long ME; Gibbs A; Kelly K; Bunn PA; Chan DC; Pallansch P; Eckhardt SG
    Clin Cancer Res; 2004 Nov; 10(21):7229-37. PubMed ID: 15534096
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics and toxicity of weekly docetaxel in older patients.
    Hurria A; Fleming MT; Baker SD; Kelly WK; Cutchall K; Panageas K; Caravelli J; Yeung H; Kris MG; Gomez J; Miller VA; D'Andrea G; Scher HI; Norton L; Hudis C
    Clin Cancer Res; 2006 Oct; 12(20 Pt 1):6100-5. PubMed ID: 17062686
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.